Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAge Labs (BIOA) Net Income towards Common Stockholders (2023 - 2026)

BioAge Labs' Net Income towards Common Stockholders history spans 2 years, with the latest figure at -$25.7 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 19.17% to -$25.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$80.4 million, a 13.34% decrease, with the full-year FY2025 number at -$80.4 million, down 13.34% from a year prior.
  • Net Income towards Common Stockholders hit -$25.7 million in Q4 2025 for BioAge Labs, down from -$20.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for BIOA hit a ceiling of -$12.7 million in Q1 2024 and a floor of -$25.7 million in Q4 2025.